RxDoctor Payments Data

Shara Mills, APRN

Family · Morganfield, KYNPI 1023350048

Payments from drug & device makers

$4,185in general payments, 2019–2025

Across 285 payments — averaging $14.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$810
  • Novo Nordisk$472
  • AstraZeneca$440
  • Lilly USA, LLC$371
  • Amgen$319
  • Pfizer$219
  • plus $2K from 32 others

What the payments were for

  • Food & beverage$4,174100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,185 in reported general payments places this provider in the 90th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$4,154
Medicare patients
96
Services billed
221

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide55$71,700
JardianceEmpagliflozin60$58,206
FarxigaDapagliflozin Propanediol36$36,030
EliquisApixaban51$31,542
TrulicityDulaglutide29$27,725
XareltoRivaroxaban18$26,531
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$25,554
MounjaroTirzepatide17$21,336
JanuviaSitagliptin Phosphate22$20,626
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr26$14,871
Breztri AerosphereBudesonide/Glycopyr/Formoterol20$12,595
GemtesaVibegron19$8,521
Albuterol Sulfate HfaAlbuterol Sulfate120$3,417
Novolog FlexpenInsulin Aspart17$2,646
SymbicortBudesonide/Formoterol Fumarate11$2,416

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$472$71,70055 claims
Boehringer IngelheimJardiance$206$58,20660 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$440$51,04167 claims
Lilly USA, LLCTrulicity, Mounjaro$371$49,06146 claims
GSKTrelegy Ellipta, Anoro Ellipta$102$40,42663 claims
PfizerEliquis, Paxlovid$219$32,97162 claims
Johnson & JohnsonXarelto$80$26,53118 claims
MerckJanuvia$12$20,62622 claims
Sumitomo Pharma America, Inc.Gemtesa$37$8,52119 claims
AbbVieSynthroid$810$1,50623 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,374 family providers in Kentucky.

Other family in Morganfield

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →